D&A at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s D&A?
- Krystal Biotech, Inc. (KRYS) reported D&A of $1.52M in Q1 2026.
- How has Krystal Biotech, Inc.'s D&A changed year-over-year?
- Krystal Biotech, Inc.'s D&A increased by 7.9% year-over-year, from $1.41M to $1.52M.
- What is the long-term trend for Krystal Biotech, Inc.'s D&A?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s D&A has grown at a 19.6% compound annual growth rate (CAGR), from $2.77M to $5.67M.
- What does D&A mean?
- The non-cash expense representing the wear and tear or expiration of assets.
- How do you interpret D&A?
- Higher values often correlate with a larger asset base, while sudden changes may indicate shifts in capital investment strategy.
- How does D&A compare across companies?
- Universal metric for all companies with significant property, plant, and equipment.